Newsstand | Page 8 | Aplastic Anemia & MDS International Foundation


Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.


Originally Published: 11/13/2018

Foundation Update Newsletter November 2018

Originally Published: 11/10/2018

Aplastic Anemia & MDS International Foundation Announces New Executive Director

Originally Published: 10/23/2018
Tuesday, October 23, 2018 - For Immediate Release APLASTIC ANEMIA & MDS INTERNATIONAL FOUNDATION ANNOUNCES NEW EXECUTIVE DIRECTOR BETHESDA, MARYLAND –  The Aplastic Anemia & MDS International Foundation (AAMDSIF), the world's leading non-profit health organization dedicated to serving patients afflicted with bone marrow failure disease, announced today that Neil Horikoshi has been named the Foundation's new Chief Executive Officer and Executive Director.  Mr. Horikoshi succeeds Kathleen Weis, who resigned from her position to pursue new opportunities.            “On behalf of the...

Genomic Breakthroughs Offer Hope for New Strategies in AML

Originally Published: 10/23/2018
Results of a deep sequencing analysis demonstrated that mutations in 8 high-risk genes are associated with an acute myeloid leukemia (AML) diagnosis. These findings, explained Hetty Carraway, MD, lay the ground work for early detection studies and novel treatment strategies. “It is pretty provocative work, pretty exciting, and it really allows us to think more deeply about how we can impact and change that trajectory for patients,” said Carraway, who is vice chair of Strategy and Enterprise Development at Taussig Cancer Institute, Cleveland Clinic.

The MDS Clinical Research Consortium

Originally Published: 10/17/2018
The MDS Clinical Research Consortium (MDS- CRC) is an unprecedented, six-institution group designed to undertake unique studies and trials to advance treatments and improve outcomes for patients with myelodysplastic syndromes (MDS). Member institutions are six academic medical centers serving a high volume of MDS patients: Cleveland Clinic Taussig Cancer Institute Dana-Farber Cancer Institute H. Lee Moffitt Cancer Center and Research Institute  MD Anderson Cancer Center Weill Medical College of Cornell University Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins The consortium is...

Towards a Cure Newsletter October 2018

Originally Published: 10/15/2018

What is Flow Cytometry?

Originally Published: 10/10/2018
Flow cytometry is the “go-to” test for diagnosing PNH.  PNH happens because of a change (mutation) in the PIG-A gene of a subset of stem cells in bone marrow. This gene controls the creation of substance that helps certain proteins to stick to the surface of blood cells. Therefore, any blood cells created by this mutated bone marrow stem cell are abnormal because they can be destroyed by the complement system, which is a component of our immune system. Using light scattering techniques and fluorescence, flow cytometry can show your doctor if any proteins are missing from the surface of blood...

Combinations May Confer Benefit in MDS Management

Originally Published: 10/10/2018
Although investigational agents are showing promise for patients with low-risk myelodysplastic syndrome (MDS), physicians are still seeking combinations that will enhance responses for patients with high-risk disease, explained Mikkael A. Sekeres, MD.

Promising Results of a Phase 1/2 Clinical Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia

Originally Published: 10/09/2018
MDS/MPN (myelodysplastic syndromes/myeloproliferative neoplasms) is a disease of the blood and bone marrow with features of both MDS and MPN.  The most common form is CMML, or chronic myelomonocitic leukemia.  In CMML, abnormal blood cells (myeloblasts and myelocytes) accumulate in the bone marrow and other organs, and they interfere with the production of healthy blood cells.  This study led by Dr. Eric Padron through the MDS Clinical Research Consortium sites showed promising results for a new CMML treatment.   This Phase I/II study was conducted by Dr. Eric Padron of the H. Lee Moffitt...

Expert Recaps Advances in AML

Originally Published: 09/26/2018
Now that physicians have access to novel therapies for patients with acute myeloid leukemia (AML) following a 30-year gap in therapeutic development, physicians must now aim to understand their optimal placement in treatment, explained Rami S. Komrokji, MD. “The landscape is changing; it’s an exciting time,” said Komrokji.